Will Seattle Genetics' ADC drug, Adcetris, become a blockbuster (sales > $1B annually) over the next several years? Yes, say some analysts. But, in order to do so, it most certainly will have to be approved for additional indications for which it is currently being tested in clinical trials. As it stands, the drug achieved sales of $269 M for the last sales year.
In addition to successes so far with Adcetris, SeaGen is adding to its own drug pipeline -- with 7 new molecules -- and has also started working with a new platform that employs a novel cytotoxic agent called pyrrolobenzodiazepine (PBD) dimer. The latter has been included in a new program aimed at CD33 (SGN-CD33A). The program also employs a new linker and a site specific conjugation technology. SeaGen hopes to parlay that into more technology agreements with the likes of Pfizer, AbbVie, Genentech, GSK, etc.
More deals equals more upfronts, milestones and royalties to keep fueling SeaGen growth. See Biopharma-reporter.
Posted by Bruce Lehr Feb 27th 2014.